As filed with the Securities and Exchange Commission on July 14, 1998.
                                                    Registration No. 333-
                    SECURITIES AND EXCHANGE COMMISSION
                          Washington, D.C. 20549
                         -----------------------
                                 FORM S-8

          REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
                         -----------------------

                         SEROLOGICALS CORPORATION
              (Exact name of issuer as specified in its charter)
        Delaware                              58-2142225 
(State or other jurisdiction of      	(I.R.S. Employer Identification
 incorporation or organization)                 	Number)

                      780 Park North Blvd., Suite 110
                         Clarkston, Georgia 30021
            (Address of principal executive offices) (Zip Code)

               ---------------------------------------------
                 SEROLOGICALS CORPORATION COMPENSATION PLAN
                        FOR NON-EMPLOYEE DIRECTORS
                        (Full titles of the Plans)
               ---------------------------------------------

                          Harold J. Tenoso, Ph.D.
                  President and Chief Executive Officer
                         Serologicals Corporation
                      780 Park North Blvd., Suite 110
                         Clarkston, Georgia 30021
                              (404) 296-5595
                    (Name, address and telephone number,
                (including area code, of agent for service)
                                Copies to:
                         David S. Rosenthal, Esq.
                        Shereff, Friedman, Hoffman
                              & Goodman, LLP
                             919 Third Avenue
                         New York, New York  10022
                              (212) 758-9500

                      CALCULATION OF REGISTRATION FEE

========================================================================
 Title of   |            |   Proposed     | Proposed     |   Amount
Securities  |   Amount   |    Maximum     |  Maximum     |     of
  to be     |   to be    | Offering Price | Aggregate    |Registration
Registered  | Registered |  Per Share (2) |Offering Price|   Fee (2)
            |            |                |    (2)       |
========================================================================
            |            |                |              |             
 Common     | 25,000     |     $31.50     | $787,500     |   $232.31
            |  shares    |                |              |          
========================================================================
(1) Pursuant to Rule 416, this Registration Statement also covers such 
additional securities as may become issuable to prevent dilution resulting 
from stock splits, stock dividends or similar transactions.

(2)  Estimated solely for the purpose of calculating the registration fee 
pursuant to Rule 457 on the basis of the average of the high and low sale 
prices of the Registrant's Common Stock as included on The NASDAQ National 
Market on July 8, 1998. 

(3)  The Registration Fee has been calculated pursuant to Rule 457 as 
follows: 25,000 multiplied by .000295 multiplied by $31.50, the average of 
the high and low sale prices of the Registrant's Common Stock as included 
on The NASDAQ National Market on July 8, 1998.


                                  PART II

                           INFORMATION REQUIRED IN
                          THE REGISTRATION STATEMENT

Item 3.  Incorporation of Documents by Reference

     The following documents, which have been filed by Serologicals 
Corporation, a Delaware corporation (the "Registrant"), with the Securities 
and Exchange Commission (the "Commission"), are incorporated herein by 
reference:

     (a) The Registrant's Annual Report on Form 10-K for the period ended 
December 28, 1997.

     (b) The Registrant's Quarterly Report on Form 10-Q for the period 
ended March 29, 1998.

     (c) The description of the Registrant's Common Stock, par value $0.01 
per share, which is contained in a registration statement filed under 
Section 12 of the Securities Exchange Act of 1934, as amended (the 
"Exchange Act"), including any amendment or report filed for the purpose of 
updating such description.

     In addition, all documents subsequently filed by the Registrant 
pursuant to Section 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior 
to the filing of a post-effective amendment which indicates that all 
securities offered have been sold or which deregisters all securities then 
remaining unsold, shall be deemed to be incorporated by reference in this 
registration statement and to be a part hereof from the time of filing of 
such documents.  Any statement contained in the documents incorporated or 
deemed to be incorporated by reference herein shall be deemed to be 
modified or superseded for purposes of this registration statement to the 
extent that a statement contained herein or in any other subsequently filed 
document which also is incorporated or deemed to be incorporated by 
reference herein modifies or supersedes such statement.  Any such statement 
so modified or superseded shall not be deemed, except as so modified or 
superseded, to constitute a part of this registration statement.

Item 4.  Description of Securities.

            Not applicable.

Item 5.  Interest of Named Experts and Counsel. 

            Not applicable.

Item 6.  Indemnification of Directors and Officers.

     The indemnification of officers and directors of the Registrant is 
governed by Section 145 of the General Corporation Law of the State of 
Delaware (the "DGCL") and the Certificate of Incorporation and By-Laws of 
the Registrant.  Subsection (a) of DGCL Section 145 empowers a corporation 
to indemnify any person who was or is a party or is threatened to be made a 
party to any threatened, pending or completed action, suit or proceeding, 
whether civil, criminal, administrative or investigative (other than an 
action by or in the right of the corporation) by reason of the fact that 
the person is or was a director, officer, employee or agent of the 
corporation, or is or was serving at the request of the corporation as a 
director, officer, employee or agent of another corporation, partnership, 
joint venture, trust or other enterprise, against expenses (including 
attorneys' fees), judgments, fines and amounts paid in settlement actually 
and reasonably incurred by the person in connection with such action, suit 
or proceeding if the person acted in good faith and in a manner the person 
reasonably believed to be in or not opposed to the best interests of the 
corporation, and, with respect to any criminal action or proceeding, had no 
reasonable cause to believe the person's conduct was unlawful. 

     Subsection (b) of DGCL Section 145 empowers a corporation to indemnify 
any person who was or is a party or is threatened to be made a party to any 
threatened, pending or completed action or suit by or in the right of the 
corporation to procure a judgment in its favor by reason of the fact that 
the person is or was a director, officer, employee or agent of the 
corporation, or is or was serving at the request of the corporation as a 
director, officer, employee or agent of another corporation, partnership, 
joint venture, trust or other enterprise against expenses (including 
attorneys' fees) actually and reasonably incurred by the person in 
connection with the defense or settlement of such action or suit if the 
person acted in good faith and in a manner the person reasonably believed 
to be in or not opposed to the best interests of the corporation and except 
that no indemnification shall be made in respect of any claim, issue or 
matter as to which such person shall have been adjudged to be liable to the 
corporation unless and only to the extent that the Delaware Court of 
Chancery or the court in which such action or suit was brought shall 
determine upon application that, despite the adjudication of liability but 
in view of all the circumstances of the case, such person is fairly and 
reasonably entitled to indemnity for such expenses which the Court of 
Chancery or such other court shall deem proper.

     DGCL Section 145 further provides that to the extent that a present or 
former director or officer is successful, on the merits or otherwise, in 
the defense of any action, suit or proceeding referred to in subsections 
(a) and (b) of Section 145, or in defense of any claim, issue or matter 
therein, such person shall be indemnified against expenses (including 
attorneys' fees) actually and reasonably incurred by such person in 
connection therewith.  In all cases in which indemnification is permitted 
under subsections (a) and (b) of Section 145 (unless ordered by a court), 
it shall be made by the corporation only as authorized in the specific case 
upon a determination that indemnification of the present or former 
director, officer, employee or agent is proper in the circumstances because 
the applicable standard of conduct has been met by the party to be 
indemnified.  Such determination must be made, with respect to a person who 
is a director or officer at the time of such determination, (1) by a 
majority vote of the directors who are not parties to such action, suit or 
proceeding, even though less than a quorum, or (2) by a committee of such 
directors designated by majority vote of such directors, even though less 
than a quorum, or (3) if there are no such directors, or if such directors 
so direct, by independent legal counsel in a written opinion, or (4) by the 
stockholders.  The statute authorizes the corporation to pay expenses 
incurred by an officer or director in advance of the final disposition of a 
proceeding upon receipt of an undertaking by or on behalf of the person to 
whom the advance will be made, to repay the advances if it shall ultimately 
be determined that he was not entitled to indemnification.  DGCL Section 
145 also provides that indemnification and advancement of expenses 
permitted thereunder are not to be exclusive of any other rights to which 
those seeking indemnification or advancement of expenses may be entitled 
under any By-law, agreement, vote of stockholders or disinterested 
directors, or otherwise.  DGCL Section 145 also authorizes the corporation 
to purchase and maintain liability insurance on behalf of its directors, 
officers, employees and agents regardless of whether the corporation would 
have the statutory power to indemnify such persons against the liabilities 
insured.

     The Amended and Restated Certificate of Incorporation of the 
Registrant, as amended (the "Certificate"), provides that no director of 
the Registrant shall be personally liable to the Registrant or its 
stockholders for monetary damages for breach of fiduciary duty as a 
director except for liability (i) for any breach of the director's duty of 
loyalty to the Registrant or its stockholders, (ii) for acts or omissions 
not in good faith or which involve intentional misconduct or a knowing 
violation of law, (iii) for paying a dividend or approving a stock 
repurchase in violation of Section 174 of the DGCL or (iv) for any 
transaction from which the director derived an improper personal benefit.

     In addition, the Certificate provides that directors, officers and 
others shall be indemnified to the fullest extent authorized by the DGCL, 
as in effect (or, to the extent indemnification is broadened, as it may be 
amended), against any and all expense, liability and loss (including 
settlement) reasonably incurred or suffered by such person in connection 
with such service.  The Certificate further provides that, to the extent 
permitted by law, expenses so incurred by any such person in defending any 
such proceeding shall, at his request, be paid by the Registrant in advance 
of the final disposition of such action or proceeding.

     The Certificate provides that the right to indemnification and the 
payment of expenses incurred in defending a proceeding in advance of its 
final disposition shall not be exclusive of any other right which any 
person may have or acquire under any law, provision of By-laws or 
otherwise.

     Pursuant to indemnification agreements with certain of its executive 
officers and directors the Registrant has agreed to indemnify such persons 
(including their respective heirs, executors and administrators) to the 
fullest extent permitted by the DGCL against all expenses and liabilities 
reasonably incurred in connection with or arising out of any action, suit 
or proceeding in which such executive officer or director may be involved 
by reason of having been a director or officer of the Registrant or any 
subsidiary thereof.

     The Registrant maintains directors and officers liability and company 
reimbursement insurance which, among other things (i) provides for payment 
on behalf of its officers and directors against loss as defined in the 
policy stemming from acts committed by directors and officers in their 
capacity as such and (ii) provides for payment on behalf of the Registrant 
against such loss but only when the Registrant shall be required or 
permitted to indemnify directors or officers for such loss pursuant to 
statutory or common law or pursuant to duly effective certificate of 
incorporation or by-law provisions.

Item 7.  Exemption from Registration Claimed.

            Not Applicable.

Item 8.  Exhibits

     The following exhibits are filed as part of this registration 
statement:

     4.1  Serologicals Corporation Compensation Plan for Non-Employee 
Directors.

     5.1  Opinion of Shereff, Friedman, Hoffman & Goodman, LLP.

     23.1  Consent of Arthur Andersen, LLP.

     23.2  Consent of Shereff, Friedman, Hoffman & Goodman, LLP (included 
in Exhibit 5.1).

     24.1  Power of Attorney (included in signature page to this 
registration statement).

Item 9. Undertakings.

     (a)  The undersigned Registrant hereby undertakes:

          (1) To file, during any period in which offers or sales are being 
              made, a post-effective amendment to this registration 
              statement:

               (i)  To include any prospectus required by section 10(a)(3) 
                    of the Securities Act of 1933;

               (ii) To reflect in the prospectus any facts or events 
                    arising after the effective date of the registration 
                    statement (or the most recent post-effective amendment 
                    thereof) which, individually or in the aggregate, 
                    represent a fundamental change in the information set 
                    forth in the registration statement.  Notwithstanding 
                    the foregoing, any increase or decrease in volume of 
                    securities offered (if the total dollar value of 
                    securities offered would not exceed that which was 
                    registered) and any deviation from the low or high end 
                    of the estimated maximum offering range may be 
                    reflected in the form of prospectus filed with the 
                    Commission pursuant to Rule 424(b) if, in the 
                    aggregate, the change in volume and price represent no 
                    more than a 20% change in the maximum aggregate 
                    offering price set forth in the "Calculation of 
                    Registration Fee" table in the effective registration 
                    statement;

              (iii) To include any material information with respect to the 
                    plan of distribution not previously disclosed in the 
                    registration statement or any material change to such 
                    information in the registration statement;

     PROVIDED, HOWEVER, that paragraphs (a)(l)(i) and (ii) do not apply if 
     the registration statement is on Form S-3 or S-8 and the information 
     required to be included in a post-effective amendment by those 
     paragraphs is contained in periodic reports filed by the Registrant 
     pursuant to section 13 or Section 15(d) of the Securities Exchange Act 
     of 1934 that are incorporated by reference in the registration 
     statement. 

          (2) That, for the purpose of determining any liability under the 
     Securities Act of 1933, each such post-effective amendment shall be 
     deemed to be a new registration statement relating to the securities 
     offered therein, and the offering of such securities at that time 
     shall be deemed to be the initial bona fide offering thereof.

          (3) To remove from registration by means of a post-effective 
     amendment any of the securities being registered which remain unsold 
     at the termination of the offering.


     (b)  The undersigned Registrant hereby undertakes that, for the 
purposes of determining any liability under the Securities Act of 1933, 
each filing of the Registrant's annual report pursuant to Section 13(a) or 
15(d) of the Securities Exchange Act of 1934 (and, where applicable, each 
filing of an employee benefit plan's annual report pursuant to Section 
15(d) of the Securities Exchange Act of 1934) that is incorporated by 
reference in the registration statement shall be deemed to be a new 
registration statement relating to the securities offered therein, and the 
offering of such securities at that time shall be deemed to be the initial 
bona fide offering thereof.

     (h)  Insofar as indemnification for liabilities arising under the 
Securities Act of 1933 may be permitted to directors, officers and 
controlling persons of the Registrant pursuant to the foregoing provisions, 
or otherwise, the Registrant has been advised that in the opinion of the 
Securities and Exchange Commission such indemnification is against public 
policy as expressed in the Act and is, therefore, unenforceable. In the 
event that a claim for indemnification against such liabilities (other than 
the payment by the Registrant of expenses incurred or paid by a director, 
officer or controlling person of the Registrant in the successful defense 
of any action, suit or proceeding) is asserted by such director, officer or 
controlling person in connection with the securities being registered, the 
Registrant will, unless in the opinion of its counsel the matter has been 
settled by controlling precedent, submit to a court of appropriate 
jurisdiction the question whether such indemnification by it is against 
public policy as expressed in the Act and will be governed by the final 
adjudication of such issue. 




                                SIGNATURES

     Pursuant to the requirements of the Securities Act of 1933, the 
Registrant certifies that it has reasonable grounds to believe that it 
meets all the requirements for filing on Form S-8 and has duly caused this 
Registration Statement to be signed on its behalf by the undersigned, 
hereunto duly authorized, in the City of Clarkston, State of Georgia, on 
this 13th day of July, 1998.

                                   SEROLOGICALS CORPORATION

                              By:  /s/ Harold J. Tenoso, Ph.D.
                                   Harold J. Tenoso, Ph.D.
                                   President, Chief Executive Officer and
                                   Director

     KNOW ALL MEN BY THESE PRESENTS, that each of the undersigned whose 
signature appears below constitutes and appoints Harold J. Tenoso, Ph.D. 
and Russell H. Plumb, and each of them (with full power of each of them to 
act alone), his true and lawful attorneys-in-fact, with full power of 
substitution and resubstitution for him and on his behalf, and in his name, 
place and stead, in any and all capacities to execute and sign any and all 
amendments or post-effective amendments to this registration statement, and 
to file the same, with all exhibits thereto, and other documents in 
connection therewith, with the Securities and Exchange Commission, hereby 
ratifying and confirming all that said attorneys-in-fact or any of them or 
their or his substitute or substitutes, may lawfully do or cause to be done 
by virtue hereof and the Registrant hereby confers like authority on its 
behalf.

     Pursuant to the requirements of the Securities Act of 1933, the 
Registration Statement has been signed below by the following persons on 
behalf of the Registrant and in the capacities and on the dates indicated.

Signature                    Title                                Date

/s/ Harold J. Tenoso, Ph.D.  President, Chief Executive       July 13, 1998
Harold J. Tenoso, Ph.D.      Officer and Director (Principal
                             Executive Officer)	

/s/ Samuel A. Penninger, Jr.    Chairman of the Board of      July 13, 1998
Samuel A. Penninger, Jr.	       Directors

___________________             Director                      July 13, 1998
James L. Currie	

/s/ Wade Fetzer III             Director                      July 13, 1998
Wade Fetzer III	

/s/Desmond H. O'Connell, Jr.    Director                      July 13, 1998
Desmond H. O'Connell, Jr.	

/s/ George M. Shaw, M.D., Ph.D. Director                      July 13, 1998
George M. Shaw, M.D., Ph.D.	

/s/ Lawrence E. Tilton          Director                      July 13, 1998
Lawrence E. Tilton	

______________________          Director                      July 13, 1998
Matthew C. Weisman	

/s/ Russell H. Plumb            Vice President, Finance and   July 13, 1998
Russell H. Plumb                Administration and Chief 
                                Financial Officer (Principal 
                                Financial and Accounting Officer)


                         SEROLOGICALS CORPORATION
                                 FORM S-8
                          REGISTRATION STATEMENT

                               EXHIBIT INDEX


Exhibit	

4.1  Serologicals Corporation Compensation Plan for Non-Employee Directors.

5.1  Opinion of Shereff, Friedman, Hoffman & Goodman, LLP.

23.1 Consent of Arthur Andersen, LLP.

23.2 Consent of Shereff, Friedman, Hoffman & Goodman, LLP (included in  
     Exhibit 5.1).

24.1 Power of Attorney (included in signature page to this registration 
     statement).
[{"type": "S-8", "sequence": "1", "secsgml_size_bytes": 22621}]
{"company-data": {"conformed-name": "SEROLOGICALS CORP", "cik": "0000767673", "assigned-sic": "2836", "irs-number": "582142225", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-59043", "film-number": "98665675"}, "business-address": {"street1": "780 PARK NORTH BLVD", "street2": "STE 110", "city": "CLARKSTON", "state": "GA", "zip": "30021", "phone": "4042965595"}, "mail-address": {"street1": "780 PARK NORTH BLVD", "street2": "STE 110", "city": "CLARKSTON", "state": "GA", "zip": "30021"}, "former-company": {"former-conformed-name": "SEROLOGICALS HOLDINGS INC", "date-changed": "19950418"}}
As filed with the Securities and Exchange Commission on July 14, 1998.
                                                    Registration No. 333-
                    SECURITIES AND EXCHANGE COMMISSION
                          Washington, D.C. 20549
                         -----------------------
                                 FORM S-8

          REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
                         -----------------------

                         SEROLOGICALS CORPORATION
              (Exact name of issuer as specified in its charter)
        Delaware                              58-2142225 
(State or other jurisdiction of      	(I.R.S. Employer Identification
 incorporation or organization)                 	Number)

                      780 Park North Blvd., Suite 110
                         Clarkston, Georgia 30021
            (Address of principal executive offices) (Zip Code)

               ---------------------------------------------
                 SEROLOGICALS CORPORATION COMPENSATION PLAN
                        FOR NON-EMPLOYEE DIRECTORS
                        (Full titles of the Plans)
               ---------------------------------------------

                          Harold J. Tenoso, Ph.D.
                  President and Chief Executive Officer
                         Serologicals Corporation
                      780 Park North Blvd., Suite 110
                         Clarkston, Georgia 30021
                              (404) 296-5595
                    (Name, address and telephone number,
                (including area code, of agent for service)
                                Copies to:
                         David S. Rosenthal, Esq.
                        Shereff, Friedman, Hoffman
                              & Goodman, LLP
                             919 Third Avenue
                         New York, New York  10022
                              (212) 758-9500

                      CALCULATION OF REGISTRATION FEE

========================================================================
 Title of   |            |   Proposed     | Proposed     |   Amount
Securities  |   Amount   |    Maximum     |  Maximum     |     of
  to be     |   to be    | Offering Price | Aggregate    |Registration
Registered  | Registered |  Per Share (2) |Offering Price|   Fee (2)
            |            |                |    (2)       |
========================================================================
            |            |                |              |             
 Common     | 25,000     |     $31.50     | $787,500     |   $232.31
            |  shares    |                |              |          
========================================================================
(1) Pursuant to Rule 416, this Registration Statement also covers such 
additional securities as may become issuable to prevent dilution resulting 
from stock splits, stock dividends or similar transactions.

(2)  Estimated solely for the purpose of calculating the registration fee 
pursuant to Rule 457 on the basis of the average of the high and low sale 
prices of the Registrant's Common Stock as included on The NASDAQ National 
Market on July 8, 1998. 

(3)  The Registration Fee has been calculated pursuant to Rule 457 as 
follows: 25,000 multiplied by .000295 multiplied by $31.50, the average of 
the high and low sale prices of the Registrant's Common Stock as included 
on The NASDAQ National Market on July 8, 1998.

                                  PART II

                           INFORMATION REQUIRED IN
                          THE REGISTRATION STATEMENT

Item 3.  Incorporation of Documents by Reference

     The following documents, which have been filed by Serologicals 
Corporation, a Delaware corporation (the "Registrant"), with the Securities 
and Exchange Commission (the "Commission"), are incorporated herein by 
reference:

     (a) The Registrant's Annual Report on Form 10-K for the period ended 
December 28, 1997.

     (b) The Registrant's Quarterly Report on Form 10-Q for the period 
ended March 29, 1998.

     (c) The description of the Registrant's Common Stock, par value $0.01 
per share, which is contained in a registration statement filed under 
Section 12 of the Securities Exchange Act of 1934, as amended (the 
"Exchange Act"), including any amendment or report filed for the purpose of 
updating such description.

     In addition, all documents subsequently filed by the Registrant 
pursuant to Section 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior 
to the filing of a post-effective amendment which indicates that all 
securities offered have been sold or which deregisters all securities then 
remaining unsold, shall be deemed to be incorporated by reference in this 
registration statement and to be a part hereof from the time of filing of 
such documents.  Any statement contained in the documents incorporated or 
deemed to be incorporated by reference herein shall be deemed to be 
modified or superseded for purposes of this registration statement to the 
extent that a statement contained herein or in any other subsequently filed 
document which also is incorporated or deemed to be incorporated by 
reference herein modifies or supersedes such statement.  Any such statement 
so modified or superseded shall not be deemed, except as so modified or 
superseded, to constitute a part of this registration statement.

Item 4.  Description of Securities.

            Not applicable.

Item 5.  Interest of Named Experts and Counsel. 

            Not applicable.

Item 6.  Indemnification of Directors and Officers.

     The indemnification of officers and directors of the Registrant is 
governed by Section 145 of the General Corporation Law of the State of 
Delaware (the "DGCL") and the Certificate of Incorporation and By-Laws of 
the Registrant.  Subsection (a) of DGCL Section 145 empowers a corporation 
to indemnify any person who was or is a party or is threatened to be made a 
party to any threatened, pending or completed action, suit or proceeding, 
whether civil, criminal, administrative or investigative (other than an 
action by or in the right of the corporation) by reason of the fact that 
the person is or was a director, officer, employee or agent of the 
corporation, or is or was serving at the request of the corporation as a 
director, officer, employee or agent of another corporation, partnership, 
joint venture, trust or other enterprise, against expenses (including 
attorneys' fees), judgments, fines and amounts paid in settlement actually 
and reasonably incurred by the person in connection with such action, suit 
or proceeding if the person acted in good faith and in a manner the person 
reasonably believed to be in or not opposed to the best interests of the 
corporation, and, with respect to any criminal action or proceeding, had no 
reasonable cause to believe the person's conduct was unlawful. 

     Subsection (b) of DGCL Section 145 empowers a corporation to indemnify 
any person who was or is a party or is threatened to be made a party to any 
threatened, pending or completed action or suit by or in the right of the 
corporation to procure a judgment in its favor by reason of the fact that 
the person is or was a director, officer, employee or agent of the 
corporation, or is or was serving at the request of the corporation as a 
director, officer, employee or agent of another corporation, partnership, 
joint venture, trust or other enterprise against expenses (including 
attorneys' fees) actually and reasonably incurred by the person in 
connection with the defense or settlement of such action or suit if the 
person acted in good faith and in a manner the person reasonably believed 
to be in or not opposed to the best interests of the corporation and except 
that no indemnification shall be made in respect of any claim, issue or 
matter as to which such person shall have been adjudged to be liable to the 
corporation unless and only to the extent that the Delaware Court of 
Chancery or the court in which such action or suit was brought shall 
determine upon application that, despite the adjudication of liability but 
in view of all the circumstances of the case, such person is fairly and 
reasonably entitled to indemnity for such expenses which the Court of 
Chancery or such other court shall deem proper.

     DGCL Section 145 further provides that to the extent that a present or 
former director or officer is successful, on the merits or otherwise, in 
the defense of any action, suit or proceeding referred to in subsections 
(a) and (b) of Section 145, or in defense of any claim, issue or matter 
therein, such person shall be indemnified against expenses (including 
attorneys' fees) actually and reasonably incurred by such person in 
connection therewith.  In all cases in which indemnification is permitted 
under subsections (a) and (b) of Section 145 (unless ordered by a court), 
it shall be made by the corporation only as authorized in the specific case 
upon a determination that indemnification of the present or former 
director, officer, employee or agent is proper in the circumstances because 
the applicable standard of conduct has been met by the party to be 
indemnified.  Such determination must be made, with respect to a person who 
is a director or officer at the time of such determination, (1) by a 
majority vote of the directors who are not parties to such action, suit or 
proceeding, even though less than a quorum, or (2) by a committee of such 
directors designated by majority vote of such directors, even though less 
than a quorum, or (3) if there are no such directors, or if such directors 
so direct, by independent legal counsel in a written opinion, or (4) by the 
stockholders.  The statute authorizes the corporation to pay expenses 
incurred by an officer or director in advance of the final disposition of a 
proceeding upon receipt of an undertaking by or on behalf of the person to 
whom the advance will be made, to repay the advances if it shall ultimately 
be determined that he was not entitled to indemnification.  DGCL Section 
145 also provides that indemnification and advancement of expenses 
permitted thereunder are not to be exclusive of any other rights to which 
those seeking indemnification or advancement of expenses may be entitled 
under any By-law, agreement, vote of stockholders or disinterested 
directors, or otherwise.  DGCL Section 145 also authorizes the corporation 
to purchase and maintain liability insurance on behalf of its directors, 
officers, employees and agents regardless of whether the corporation would 
have the statutory power to indemnify such persons against the liabilities 
insured.

     The Amended and Restated Certificate of Incorporation of the 
Registrant, as amended (the "Certificate"), provides that no director of 
the Registrant shall be personally liable to the Registrant or its 
stockholders for monetary damages for breach of fiduciary duty as a 
director except for liability (i) for any breach of the director's duty of 
loyalty to the Registrant or its stockholders, (ii) for acts or omissions 
not in good faith or which involve intentional misconduct or a knowing 
violation of law, (iii) for paying a dividend or approving a stock 
repurchase in violation of Section 174 of the DGCL or (iv) for any 
transaction from which the director derived an improper personal benefit.

     In addition, the Certificate provides that directors, officers and 
others shall be indemnified to the fullest extent authorized by the DGCL, 
as in effect (or, to the extent indemnification is broadened, as it may be 
amended), against any and all expense, liability and loss (including 
settlement) reasonably incurred or suffered by such person in connection 
with such service.  The Certificate further provides that, to the extent 
permitted by law, expenses so incurred by any such person in defending any 
such proceeding shall, at his request, be paid by the Registrant in advance 
of the final disposition of such action or proceeding.

     The Certificate provides that the right to indemnification and the 
payment of expenses incurred in defending a proceeding in advance of its 
final disposition shall not be exclusive of any other right which any 
person may have or acquire under any law, provision of By-laws or 
otherwise.

     Pursuant to indemnification agreements with certain of its executive 
officers and directors the Registrant has agreed to indemnify such persons 
(including their respective heirs, executors and administrators) to the 
fullest extent permitted by the DGCL against all expenses and liabilities 
reasonably incurred in connection with or arising out of any action, suit 
or proceeding in which such executive officer or director may be involved 
by reason of having been a director or officer of the Registrant or any 
subsidiary thereof.

     The Registrant maintains directors and officers liability and company 
reimbursement insurance which, among other things (i) provides for payment 
on behalf of its officers and directors against loss as defined in the 
policy stemming from acts committed by directors and officers in their 
capacity as such and (ii) provides for payment on behalf of the Registrant 
against such loss but only when the Registrant shall be required or 
permitted to indemnify directors or officers for such loss pursuant to 
statutory or common law or pursuant to duly effective certificate of 
incorporation or by-law provisions.

Item 7.  Exemption from Registration Claimed.

            Not Applicable.

Item 8.  Exhibits

     The following exhibits are filed as part of this registration 
statement:

     4.1  Serologicals Corporation Compensation Plan for Non-Employee 
Directors.

     5.1  Opinion of Shereff, Friedman, Hoffman & Goodman, LLP.

     23.1  Consent of Arthur Andersen, LLP.

     23.2  Consent of Shereff, Friedman, Hoffman & Goodman, LLP (included 
in Exhibit 5.1).

     24.1  Power of Attorney (included in signature page to this 
registration statement).

Item 9. Undertakings.

     (a)  The undersigned Registrant hereby undertakes:

          (1) To file, during any period in which offers or sales are being 
              made, a post-effective amendment to this registration 
              statement:

               (i)  To include any prospectus required by section 10(a)(3) 
                    of the Securities Act of 1933;

               (ii) To reflect in the prospectus any facts or events 
                    arising after the effective date of the registration 
                    statement (or the most recent post-effective amendment 
                    thereof) which, individually or in the aggregate, 
                    represent a fundamental change in the information set 
                    forth in the registration statement.  Notwithstanding 
                    the foregoing, any increase or decrease in volume of 
                    securities offered (if the total dollar value of 
                    securities offered would not exceed that which was 
                    registered) and any deviation from the low or high end 
                    of the estimated maximum offering range may be 
                    reflected in the form of prospectus filed with the 
                    Commission pursuant to Rule 424(b) if, in the 
                    aggregate, the change in volume and price represent no 
                    more than a 20% change in the maximum aggregate 
                    offering price set forth in the "Calculation of 
                    Registration Fee" table in the effective registration 
                    statement;

              (iii) To include any material information with respect to the 
                    plan of distribution not previously disclosed in the 
                    registration statement or any material change to such 
                    information in the registration statement;

     PROVIDED, HOWEVER, that paragraphs (a)(l)(i) and (ii) do not apply if 
     the registration statement is on Form S-3 or S-8 and the information 
     required to be included in a post-effective amendment by those 
     paragraphs is contained in periodic reports filed by the Registrant 
     pursuant to section 13 or Section 15(d) of the Securities Exchange Act 
     of 1934 that are incorporated by reference in the registration 
     statement. 

          (2) That, for the purpose of determining any liability under the 
     Securities Act of 1933, each such post-effective amendment shall be 
     deemed to be a new registration statement relating to the securities 
     offered therein, and the offering of such securities at that time 
     shall be deemed to be the initial bona fide offering thereof.

          (3) To remove from registration by means of a post-effective 
     amendment any of the securities being registered which remain unsold 
     at the termination of the offering.

     (b)  The undersigned Registrant hereby undertakes that, for the 
purposes of determining any liability under the Securities Act of 1933, 
each filing of the Registrant's annual report pursuant to Section 13(a) or 
15(d) of the Securities Exchange Act of 1934 (and, where applicable, each 
filing of an employee benefit plan's annual report pursuant to Section 
15(d) of the Securities Exchange Act of 1934) that is incorporated by 
reference in the registration statement shall be deemed to be a new 
registration statement relating to the securities offered therein, and the 
offering of such securities at that time shall be deemed to be the initial 
bona fide offering thereof.

     (h)  Insofar as indemnification for liabilities arising under the 
Securities Act of 1933 may be permitted to directors, officers and 
controlling persons of the Registrant pursuant to the foregoing provisions, 
or otherwise, the Registrant has been advised that in the opinion of the 
Securities and Exchange Commission such indemnification is against public 
policy as expressed in the Act and is, therefore, unenforceable. In the 
event that a claim for indemnification against such liabilities (other than 
the payment by the Registrant of expenses incurred or paid by a director, 
officer or controlling person of the Registrant in the successful defense 
of any action, suit or proceeding) is asserted by such director, officer or 
controlling person in connection with the securities being registered, the 
Registrant will, unless in the opinion of its counsel the matter has been 
settled by controlling precedent, submit to a court of appropriate 
jurisdiction the question whether such indemnification by it is against 
public policy as expressed in the Act and will be governed by the final 
adjudication of such issue. 

                                SIGNATURES

     Pursuant to the requirements of the Securities Act of 1933, the 
Registrant certifies that it has reasonable grounds to believe that it 
meets all the requirements for filing on Form S-8 and has duly caused this 
Registration Statement to be signed on its behalf by the undersigned, 
hereunto duly authorized, in the City of Clarkston, State of Georgia, on 
this 13th day of July, 1998.

                                   SEROLOGICALS CORPORATION

                              By:  /s/ Harold J. Tenoso, Ph.D.
                                   Harold J. Tenoso, Ph.D.
                                   President, Chief Executive Officer and
                                   Director

     KNOW ALL MEN BY THESE PRESENTS, that each of the undersigned whose 
signature appears below constitutes and appoints Harold J. Tenoso, Ph.D. 
and Russell H. Plumb, and each of them (with full power of each of them to 
act alone), his true and lawful attorneys-in-fact, with full power of 
substitution and resubstitution for him and on his behalf, and in his name, 
place and stead, in any and all capacities to execute and sign any and all 
amendments or post-effective amendments to this registration statement, and 
to file the same, with all exhibits thereto, and other documents in 
connection therewith, with the Securities and Exchange Commission, hereby 
ratifying and confirming all that said attorneys-in-fact or any of them or 
their or his substitute or substitutes, may lawfully do or cause to be done 
by virtue hereof and the Registrant hereby confers like authority on its 
behalf.

     Pursuant to the requirements of the Securities Act of 1933, the 
Registration Statement has been signed below by the following persons on 
behalf of the Registrant and in the capacities and on the dates indicated.

Signature                    Title                                Date

/s/ Harold J. Tenoso, Ph.D.  President, Chief Executive       July 13, 1998
Harold J. Tenoso, Ph.D.      Officer and Director (Principal
                             Executive Officer)	

/s/ Samuel A. Penninger, Jr.    Chairman of the Board of      July 13, 1998
Samuel A. Penninger, Jr.	       Directors

___________________             Director                      July 13, 1998
James L. Currie	

/s/ Wade Fetzer III             Director                      July 13, 1998
Wade Fetzer III	

/s/Desmond H. O'Connell, Jr.    Director                      July 13, 1998
Desmond H. O'Connell, Jr.	

/s/ George M. Shaw, M.D., Ph.D. Director                      July 13, 1998
George M. Shaw, M.D., Ph.D.	

/s/ Lawrence E. Tilton          Director                      July 13, 1998
Lawrence E. Tilton	

______________________          Director                      July 13, 1998
Matthew C. Weisman	

/s/ Russell H. Plumb            Vice President, Finance and   July 13, 1998
Russell H. Plumb                Administration and Chief 
                                Financial Officer (Principal 
                                Financial and Accounting Officer)

                         SEROLOGICALS CORPORATION
                                 FORM S-8
                          REGISTRATION STATEMENT

                               EXHIBIT INDEX

Exhibit	

4.1  Serologicals Corporation Compensation Plan for Non-Employee Directors.

5.1  Opinion of Shereff, Friedman, Hoffman & Goodman, LLP.

23.1 Consent of Arthur Andersen, LLP.

23.2 Consent of Shereff, Friedman, Hoffman & Goodman, LLP (included in  
     Exhibit 5.1).

24.1 Power of Attorney (included in signature page to this registration 
     statement).